In glaucoma, an early insight regarding the influence of RAS in IOP was described in1988: Constad et al. showed that lower IOP resulted from the use of an ACE1inhibitor in glaucoma patients(9).Recently, losartan (an angiotensin receptor type 1 inhibitor) was proposed for usein glaucoma treatment(10).Moreover, stimulation of ACE2 with diminazene aceturate was shown to causeproduction of angiotensin-(1-7) [Ang-(1-7)] and IOP reduction in experimentalrats(11). This evidence concerns the gene ACE2 and glaucoma.